Efficacy of Sandostatin® LAR® (long‐acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy
- 16 February 2004
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 60 (3), 375-381
- https://doi.org/10.1111/j.1365-2265.2004.01992.x
Abstract
Background and objectives Somatostatin analogues have been used as an adjunct to surgery and radiotherapy in the treatment of acromegaly for over 15 years, but debate surrounds their use as primary therapy. Newman suggested that octreotide was equally effective as primary or adjuvant therapy, but the effects of previous surgery/radiotherapy may have led to a preselection bias. In an attempt to eliminate this bias, the efficacy of the depot somatostatin analogue Sandostatin® LAR® as primary and adjuvant therapy has been assessed using GH and IGF‐I levels at diagnosis as baseline values. design We retrospectively analysed the GH and IGF‐I data from a large multicentre study in which patients’ biochemical response to treatment with the depot somatostatin analogue Sandostatin LAR as primary and adjuvant therapy was assessed. We used GH and IGF‐I levels at diagnosis as baseline values to eliminate any preselection bias. patients and results In 91 patients (42 male) studied, mean serum GH fell from 36·2 ± 3·3 µg/l (SEM) at diagnosis to 2·2 ± 0·2 µg/l after 48 weeks of treatment (P < 0·0001). In the primary (n = 34) and adjuvant (n = 57) therapy groups, mean GH fell from 30·7 ± 5·7 to 2·6 ± 0·4 µg/l (P < 0·0001) and from 39·5 ± 4·1 to 2·0 ± 0·2 µg/l (P < 0·0001), respectively. Sixty‐two percent of patients in the primary therapy group and 70% in the adjuvant therapy group achieved GH < 2 µg/l. Serum IGF‐I levels were available in 67 patients (34 male). In the primary therapy group (n = 25) mean IGF‐I fell from 764 ± 68 to 414 ± 31 µg/l (P < 0·0001) at 48 weeks. In the adjuvant therapy group (n = 42) mean IGF‐I was 666 ± 50 µg/l, falling to 384 ± 30 µg/l (P < 0·0001) at 48 weeks. 72% of patients achieved normal age‐related IGF‐I‐values. There were no statistically significant differences in GH or IGF‐I levels between the primary and adjuvant therapy groups at diagnosis, pre Sandostatin LAR or after 48 weeks of treatment. conclusion This retrospective study demonstrates that in a group of patients with similar diagnostic GH and IGF‐I levels, Sandostatin LAR was equally effective as primary therapy in acromegalic patients as in patients previously treated with surgery and/or radiotherapy.Keywords
This publication has 16 references indexed in Scilit:
- Long-Term Safety and Efficacy of Depot Long-Acting Somatostatin Analogs for the Treatment of AcromegalyJournal of Clinical Endocrinology & Metabolism, 2002
- Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in AcromegalyJournal of Clinical Endocrinology & Metabolism, 2001
- Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)Journal of Clinical Endocrinology & Metabolism, 2000
- Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experienceClinical Endocrinology, 1999
- Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for AcromegalyJournal of Clinical Endocrinology & Metabolism, 1998
- Transsphenoidal Microsurgery for Growth Hormone-Secreting Pituitary Adenomas: Initial Outcome and Long-Term ResultsJournal of Clinical Endocrinology & Metabolism, 1998
- Octreotide as Primary Therapy for AcromegalyJournal of Clinical Endocrinology & Metabolism, 1998
- Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cureClinical Endocrinology, 1996
- Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study [published erratum appears in J Clin Endocrinol Metab 1995 Nov;80(11):3238]Journal of Clinical Endocrinology & Metabolism, 1995
- Octreotide Treatment of AcromegalyAnnals of Internal Medicine, 1992